The Impact of Acupuncture on Biomarkers of Brain Injury and Inflammatory Response in Migraine
ACUPMIGRAINE
1 other identifier
interventional
75
1 country
1
Brief Summary
Migraine is more than just a headache-it can involve changes in the brain and inflammation. Recent research suggests that acupuncture may help by calming pain signals and reducing inflammation in the body. Scientists are studying whether acupuncture can also lower certain markers in the blood that show brain stress or inflammation. While more research is needed, acupuncture is considered safe and may reduce the number and severity of migraine attacks for many people. Acupuncture has been used for over 40 years in our practice to manage acute and chronic pain, including migraines. When performed by trained physicians, it is safe and typically reduces headache frequency and intensity, as well as nausea and vomiting, lowering the need for pain medication. Investigators are exploring three different ways to help manage migraine headaches using gentle stimulation techniques. These include laser acupuncture, electroacupuncture, and traditional acupuncture. Investigators want to see which method works best for reducing migraine symptoms. Investigators will look at how participants feel after treatment and also check blood samples for signs of inflammation and certain substances linked to migraines, such as calcitonin gene-related peptide (CGRP) and markers of brain stress. Investigators have a goal to find safe and effective options that can improve migraine care and help people feel better.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 3, 2025
CompletedFirst Submitted
Initial submission to the registry
November 18, 2025
CompletedFirst Posted
Study publicly available on registry
December 18, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 15, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
July 15, 2026
ExpectedDecember 18, 2025
November 1, 2025
4 months
November 18, 2025
December 5, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
NRS 3
Pain intensity three months after treatment measured with NRS (Numeric rate scale) from 0 (for = pain) to 10 (maximal pain)
Baseline and three months from last acupuncture stimulation
Secondary Outcomes (3)
HIT- 6
Baseline and three months from last acupuncture stimulation
MIDAS
Baseline and three months from last acupuncture stimulation
Biomarkers of brain injury and inflammatory response
Baseline, day of last acupuncture stimulation and three months from last acupuncture stimulation
Study Arms (3)
Standard acupuncture
ACTIVE COMPARATORTraditional Acupuncture - standard acupuncture treatment on local scalp and distal points
Electroacupuncture
ACTIVE COMPARATORElectroacupuncture - standard acupuncture on local scalp points combined with gentle electrical stimulation of the needles placed on distal points
Laser Acupuncture
ACTIVE COMPARATORLaser Acupuncture - standard acupuncture on local scalp points combined with low-level laser instead of needles on distal acupuncture points
Interventions
standard acupuncture on the scalp and distal acupuncture point that will not be stimulated with electro or laser device
Electroacupuncture - distal acupuncture points will be stimulated will electronic device that is used for electroacupuncture
Distal acupuncture points will be stimulated with laser needles
Eligibility Criteria
You may qualify if:
- Adults diagnosed with migraine headaches according to the International Classification of Headache Disorders (ICHD).
- Patients who are not currently receiving monoclonal antibodies targeting CGRP (Calcitonin Gene-Related Peptide)
You may not qualify if:
- Use of CGRP monoclonal antibody therapy within the past 6 months.
- Other significant neurological or systemic conditions that could interfere with study outcomes.
- Pregnancy or breastfeeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinical department of anaesthesiology and surgical intensive therapy University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
Related Publications (3)
Xu S, Yu L, Luo X, Wang M, Chen G, Zhang Q, Liu W, Zhou Z, Song J, Jing H, Huang G, Liang F, Wang H, Wang W. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ. 2020 Mar 25;368:m697. doi: 10.1136/bmj.m697.
PMID: 32213509RESULTLiu Y, Yu S. Recent Approaches and Development of Acupuncture on Chronic Daily Headache. Curr Pain Headache Rep. 2016 Jan;20(1):4. doi: 10.1007/s11916-015-0535-7.
PMID: 26700695RESULTPeters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34.
PMID: 30681821RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lea Rupert, MD
Clinical department of anaesthesiology and surgical intensive therapy University Medical Centre Ljubljana
- STUDY CHAIR
Jasmina Markovic Bozic, MD, Phd, Asist. Prof.
Clinical department of anaesthesiology and surgical intensive therapy University Medical Centre Ljubljana
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 18, 2025
First Posted
December 18, 2025
Study Start
November 3, 2025
Primary Completion
March 15, 2026
Study Completion (Estimated)
July 15, 2026
Last Updated
December 18, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share